

Too much iron: A masked foe for leukemias

Eolia Brissot, Delphine G Bernard, Olivier Loréal, Pierre Brissot, Marie-Bérengère Troadec

▶ To cite this version:

Eolia Brissot, Delphine G Bernard, Olivier Loréal, Pierre Brissot, Marie-Bérengère Troadec. Too much iron: A masked foe for leukemias. Blood Reviews, 2020, 39, pp.100617. 10.1016/j.blre.2019.100617 . hal-02472239

HAL Id: hal-02472239 https://univ-rennes.hal.science/hal-02472239v1

Submitted on 23 Mar 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	Too much iron: a masked foe for leukemias	
2		
3	BRISSOT Eolia*	
4	Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, APHP, Paris, France ;	
5 6	Sorbonne Universités, UPMC Univ. Paris 06, AP-HP, Centre de recherche Saint-Antoine, UMR-S938, Paris, France	
7	eolia.brissot@aphp.fr	
8	Tel.: +33 1 49 28 31 93	
9		
10	BERNARD Delphine	
11	Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France	
12	delphine.bernard@univ-brest.fr	
13	Tel.: +33 2 98 01 60 00	
14		
15	LORÉAL Olivier	
16	Institut NuMeCan, Inserm U-1241, Univ Rennes 1, Rennes, France	
17	olivier.loreal@univ-rennes1.fr	
18	Tel.: +33 2 99 54 37 37	
19		
20	BRISSOT Pierre	
21	Institut NuMeCan, Inserm U-1241, Univ Rennes 1, Rennes, France	
22	pierre.brissot@gmail.com	
23	Tel.: +33 2 99 54 37 37	
24		
25	TROADEC Marie-Bérengère*	
26	Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France	
27	CHRU Brest, Service de génétique, Unité de cytogénétique, France	
28	marie-berengere.troadec@univ-brest.fr	
29	Tel.: +33 2 98 01 64 55	
30		
31		

- 32 * CORRESPONDING AUTHORS:
- 33 E-mail addresses:
- 34 <u>eolia.brissot@aphp.fr</u> (E. Brissot)
- 35 <u>marie-berengere.troadec@univ-brest.fr</u> (M-B. Troadec)
- 36
- 37

ABSTRACT

39 The role of iron in non-erythroid hematopoietic lineages and its implication in hemato-oncogenesis are 40 still debated. Iron exerts an important role on hematopoietic stem cell transformation and on mature 41 white blood cell differentiation. Iron acts experimentally as an oncogenic cofactor but its exact role in the 42 transformation of the myelodysplastic syndrome into leukemia continues to be discussed. Body iron overload frequently develops mainly as the result of multiple erythrocyte transfusions in patients with 43 44 leukemia or myelodysplastic syndrome, and, in the latter, as a result of increased ineffective 45 erythropoiesis. Iron overload, especially through the deleterious effects of reactive oxygen species, leads 46 to organ damage that likely impacts the global outcome of patients, especially after hematopoietic stem 47 cell transplantation (HSCT). In these pathological settings (before and after HSCT), oral iron chelation 48 should be considered whenever body iron overload has been firmly established, ideally by magnetic 49 resonance imaging. 50

- 51
- 52

KEYWORDS

- Iron; leukemia; myelodysplastic syndrome; hematopoietic stem cell transplantation; oral chelation;phlebotomy.
- 55

56 **ABBREVIATIONS**

- 57 ALL: acute lymphoblastic leukemia
- 58 AML: acute myeloid leukemia
- 59 DFX: deferasirox
- 60 HSC: hematopoietic stem cell
- 61 HSCT: hematopoietic stem cell transplantation
- 62 LIC: liver iron content
- 63 LPI: labile plasma iron

- 64 LPS: lipopolysaccharide
- 65 MDS: myelodysplastic syndromes
- 66 MDS-RS: myelodysplastic syndrome with ring sideroblasts
- 67 MSC: mesenchymal stromal cell
- 68 MRI: magnetic resonance imaging
- 69 NTBI: non transferrin-bound iron
- 70 ROS: reactive oxygen species

71

INTRODUCTION

72 The crosstalk between iron and hematology is illustrated by the well-known relationship between 73 iron and erythrocytes where iron is required in order to sustain erythrocyte production within the 74 bone marrow. Iron is abundantly found in the blood within these erythrocytes, and released during 75 erythrocyte degradation mainly within the spleen (1). The goal of the present review, beyond 76 examining the role of iron in the erythroid lineage, is to focus on the relationship between iron and 77 hematopoietic cells, with a special emphasis on iron overload and leukemias. Systemic iron overload 78 frequently develops in leukemias, mainly due to transfusion therapy (2-4). Another mechanism, 79 involved in myelodysplastic syndromes (MDS) in particular (hematologic malignancies characterized 80 by a risk of progression to acute myeloid leukemia (AML)), is ineffective erythropoiesis (5). Ineffective 81 erythropoiesis, notably through increased bone marrow production of the hormone erythroferrone 82 (6), reduces hepcidin expression (7), leading to increased digestive absorption of iron and increased 83 splenic release of the iron originating from erythrophagocytosis (8). After a reminder on the 84 physiological role of iron in bone marrow stem cells and mature white blood cells, the following 85 pathological aspects will be considered: the body iron load status in leukemia patients both at 86 diagnosis and during medical care, the negative consequences of iron excess on patient outcome, 87 especially after hematopoietic stem cell transplantation (HSCT), and the clinical interest of removing excessive iron in leukemia patients. 88

89

1. |

91

92

90

1. IRON: HOMEOSTASIS AND FUNCTIONAL LINKS BETWEEN IRON AND BONE MARROW

1.1. General iron homeostasis

Iron is critical for life due to its major roles in oxygen transport, key enzymatic reactions (such
as DNA synthesis or detoxification) and the growth of microorganisms. In vertebrates, iron is
abundantly present within red blood cells and in a tiny but functionally essential amount in

96 the plasma; this plasma iron ensures the delivery of iron to the bone marrow primarily for 97 erythrocyte synthesis and to all living cells (9-11) (Fig. 1). Iron is stored in parenchymal cells 98 (essentially hepatocytes where it is sequestered within ferritin molecules) and in 99 macrophages (mainly splenic macrophages). The only physiological source of iron for the 100 body is alimentary, explaining the risk of iron deficiency when this input is limited. In the case of excessive iron input, either by increased intestinal absorption (such as in 101 102 hemochromatosis) or by excessive parenteral entry (due to multiple transfusions or excessive 103 iron supplementation), there is no effective possibility for the human body to adapt its 104 excretory pathways, which explains the risk of iron overload. This dual vulnerability to iron deprivation and to iron excess explains that iron homeostasis is very finely regulated, both at 105 106 the systemic and cellular levels. At the systemic level, the key role belongs to hepcidin, the 107 major hormone regulating iron metabolism. Hepcidin is a small peptide of 25 amino acids, 108 essentially produced by hepatocytes, that decreases the plasma iron concentration. The 109 decreasing effect exerted by hepcidin on the plasma iron level is mediated by the degradation 110 of ferroportin, which is the only known protein to export cellular iron into the plasma. This 111 hepcidin-ferroportin duo acts at two main sites, duodenal enterocytes and the spleen. At the digestive level, through the combined action of ferroportin export and hephaestin oxidation, 112 iron is delivered to plasma transferrin which principally targets the bone marrow in order to 113 114 produce new red blood cells (see Table 1 for names and symbols of the genes). In the spleen, 115 iron originating from erythrophagocytosis is exported into the plasma through ferroportin, oxidized by ceruloplasmin, bound to transferrin and recycled toward the bone marrow. Many 116 117 factors can regulate hepcidin expression. Body iron load status is a major regulator: a 118 decrease in iron levels (either plasma transferrin saturation level and/or intrahepatocyte iron 119 load level) leads to lower hepcidin production in order to counteract iron deficiency. The 120 reverse phenomenon occurs in the case of iron overload. Inflammation is also an important 121 regulatory factor, in which the IL6-STAT3 pathway is involved to increase hepcidin production.

122 The erythroferrone hormone, mainly produced by the bone marrow, is another important 123 regulatory factor (12, 13). Its increased production in the case of dyserythropoiesis leads to 124 the downregulation of hepcidin expression. This decrease in hepcidin production may 125 override the expected increased hepcidin expression in the presence of coexisting iron 126 excess. At the cellular level, iron homeostasis is mainly ensured at a post-transcriptional level 127 by the iron regulatory proteins (IRP). Schematically, in a context of cellular iron deficiency, 128 IRP1 and IRP2 bind to iron regulatory elements (IRE) located in the 5' or 3' untranslated 129 transcribed region (UTR) of the mRNA involved in the entry (TFR1), storage (ferritin) and 130 export of iron (ferroportin). This leads, through different mechanisms (inhibition of 131 translation or stabilization of transcripts), to increased cellular iron entry and decreased 132 cellular iron storage and egress. The reverse effects occur in the case of cellular iron overload, 133 where IRP1 and IRP2 lose their capacity to bind to IRE. Any acquired and/or genetic 134 abnormality in these regulatory processes may lead to iron-related disorders.

Altogether, many of the players involved in iron metabolism are now described at the molecular level. They are transporters, receptors, oxido-reductases, sensors, chelators, regulatory pathway players and hormones. Their interdependency and fine-tuning explain the functional relationship between diverse tissues and iron.

- 139
- 140

141 1.2. The functional relationship between iron and bone marrow

There is a very close relationship between iron and bone marrow that can be considered through two reciprocal perspectives. On the one hand, there is an iron flux toward the bone marrow that is physiologically required to sustain crucial hematopoietic functions, and which, when excessive, can exert deleterious effects on hematopoiesis (14-16). On the other hand, the bone marrow not only ensures the delivery into the blood of the different hematological cells involved in iron

- 147 metabolism (the erythrocytes in first line), but also plays a key role in the systemic distribution of148 iron.
- 149
- 150 1.2.1. From iron to the bone marrow: iron is used by all hematopoietic lineages
- 151
- 152 1.2.1.1. Iron and bone marrow stem cells: hematopoietic and mesenchymal stromal cells (HSC and153 MSC)

154 Iron, through its propensity for producing reactive oxygen species (ROS), exerts a determining role 155 on the fate of HCS (14, 15) and its impact depends on the dose of iron. Low ROS levels are required 156 for HSC renewal. ROS levels also fine-tune HSC differentiation: very low levels can hamper HSC 157 differentiation, whereas increasing ROS levels favor their differentiation. On the contrary, very high 158 ROS levels promote stem cell exhaustion and death by causing cytotoxicity through the binding of ROS to lipid membranes, proteins and DNA, promoting deleterious oxidation of these 159 160 macromolecules. Excessive iron impairs hematopoiesis by inducing apoptosis and cell cycle arrest 161 (17), and decreases the ratio and clonogenic function of hematopoietic stem and progenitor stem cells (18). Iron also plays a role in other cells in the hematopoietic niche. Iron increases the 162 163 proliferation of human MSCs and accelerates their entry into S-phase (19). In contrast, excess iron 164 negatively impacts the hematopoietic microenvironment, as shown by the delayed hematopoietic 165 reconstitution observed in mice overloaded by iron-dextran and transplanted with bone marrow 166 from untreated mice (20). Moreover, in MDS patients, iron overload has been shown to promote 167 mitochondrial fragmentation of mesenchymal stromal cells (21).

168

169 1.2.1.2. Iron in white cell lineages

170 A short history... In 1952, CB Laurell wrote that "nobody has investigated whether the white blood 171 cells have any function in iron transportation or hemoglobin breakdown, in spite of the fact that 172 leucocytes have a relatively high iron content" in a seminal review entitled "Plasma iron and iron 173 transport in the organism" (22). Twenty-two years later, Summers and Jacobs (23, 24) showed that 174 monocyte ferritin content was approximately seven times higher than that in lymphocytes or 175 polymorphs in normal subjects. They also reported that the ferritin content increased during 176 anemia of chronic disease in lymphocytes, monocytes and polymorphs. Iron uptake by lymphocytes 177 was also greatly increased during iron deficiency anemia. At the same time, Worwood et al. 178 reported that leukemia cells had a markedly increased ferritin content (25). We will now consider 179 the present state of knowledge about iron content, function and impact in white blood cells.

180 Iron and monocytes-macrophages. Monocytes are known to correspond to circulating 181 macrophages. Iron is required for the differentiation of peripheral blood monocyte precursors into 182 functional macrophages; iron deprivation by desferrioxamine generates macrophages unable to 183 develop a mature phenotype, with an impaired capacity for phagocytosis (23). It is also well known 184 that iron sequestration occurs within macrophages during inflammation. Importantly, interleukin 185 6 (IL-6), which is produced by macrophages in response to pathogen-associated molecular patterns, 186 activates the STAT3 signaling pathway leading to hyperhepcidinemia, and therefore to the 187 degradation of ferroportin, and eventually to hyposideremia. It has also been shown that 188 inflammation can cause hyposideremia through a hepcidin-independent mechanism involving the 189 transcriptional downregulation of ferroportin (26). Depending on their microenvironment and 190 cooperation with lymphocytes, monocytes polarize into active macrophage populations that are 191 subdivided into activated M1 macrophages exerting proinflammatory and antitumor activities, and 192 into activated M2 macrophages that are immunosuppressive and promote tumor activity. 193 Importantly, iron modulates this macrophage polarization, increasing the M2 phenotype and decreasing the M1 proinflammatory lipopolysaccharide (LPS)-induced response (27). In a mouse 194 195 model of hemochromatosis (a genetic iron overload disease), attenuated inflammatory responses

196 to Salmonella infection or LPS were observed compared to non-hemochromatosis control mice. 197 This study demonstrates a novel role of iron in the regulation of macrophage IL-6 cytokine mRNA 198 translation (28). This result is coherent with a previous report that showed that $TNF\alpha$ 199 concentrations were decreased in the supernatants of monocytes from hemochromatosis patients 200 (29). Youssef et al. (30) reported that, following increased erythrophagocytosis, splenic 201 macrophages undergo ferroptosis and are replaced by circulating monocytes and local cell division. 202 Haschka et al. (31) found that classical (CD14⁺, CD16⁻) and intermediate (CD14⁺, CD16⁺) subsets of 203 human monocytes are involved in clearing non-transferrin-bound iron (NTBI) and damaged red 204 blood cells. Therefore monocytes may play a role in limiting iron toxicity in iron overload conditions.

Iron and dendritic cells. Kramer *et al.* showed that differentiation from human peripheral blood
 monocyte precursors into functional dendritic cells requires iron and is dependent on the
 expression of the cyclin-dependent kinase inhibitor p21 (32). Iron depletion by the chelator
 desferrioxamine produced undifferentiated dendritic cells unable to stimulate naive allogeneic T
 lymphocytes. Olakanmi *et al.* showed that lung myeloid dendritic cells acquire iron from various
 types of extracellular sources (iron-citrate, iron-transferrin and iron-lactoferrin) (33).

211 Iron and neutrophils. The positive role of iron on granulopoiesis is suggested by studies in anemic 212 Belgrade (b/b) rats. Indeed, an increased proliferation of granulocytic cells is observed in iron-213 treated b/b rats (34). Importantly, neutrophils impact iron metabolism during inflammation by 214 secreting lactoferrin (35, 36). Lactoferrin is an iron-binding multifunctional glycoprotein secreted 215 by neutrophils and exocrine glands. During inflammation or infection, the plasma lactoferrin 216 concentration increases through the recruitment of neutrophils (37). The antibacterial and 217 antibiofilm activity of lactoferrin is dependent, although not exclusively, on its iron-binding affinity. 218 However, no evidence has been brought forward regarding a significant impact of lactoferrin on 219 human granulopoiesis (38).

Iron and eosinophils. To our knowledge, the sole interference of iron with the eosinophil lineage
 involves the role of iron-loaded lactoferrin. Bovine lactoferrin regulates the pathway implicating
 the CD11b and CD49d integrins and the MIP-1α and MCP-1 chemokines in granulocyte-macrophage
 colony-stimulating factor (GM-CSF)-treated human eosinophils (39).

224 Iron and lymphocytes. Transferrin receptor 1 (TFR1)-mediated iron uptake is essential for 225 lymphocyte proliferation (40). Iron also plays a key role in the differentiation of T lymphocytes. The 226 absence of TFR1 in genetically modified mice leads to a total arrest of T lymphopoiesis at a very 227 early stage of maturation, and the function and impact of iron on B lymphocytes is less pronounced 228 (41). A significant increase in lymphocyte number is observed in iron overload situations such as 229 human HFE-related hemochromatosis (42). The number of CD8+ T lymphocytes negatively correlates with the severity of iron overload in HFE-related hemochromatosis (43). Lymphocytes 230 231 can also internalize iron through pathways involving non-transferrin-bound iron (NTBI) (44, 45), 232 supporting the view that T lymphocytes may play a protective role against the consequences of 233 iron excess. This result is in accordance with the proposal that T lymphocytes act as a first line 234 protective barrier against the deleterious effects of iron excess (46). The cellular localization of iron 235 was not addressed in this study but the authors suggest that it may be stored within ferritin, in agreement with the demonstration that T lymphocytes are able to synthetize H-ferritin (47). 236

In summary, all hematopoietic lineages use iron for proliferation and/or differentiation functions, including the white blood cell lineages. The physiological flux of iron toward the bone marrow exerts proliferative and differentiating effects on HSCs and MSCs. An excess of iron within the bone marrow impairs these processes, mainly through an excessive production of ROS. Regarding mature white blood cells, iron is required for the maturation and phagocytotic activity of peripheral monocytes, the differentiation of monocytes into functional dendritic cells, the proliferation of granulocytic cells, and T lymphopoiesis.

243

244

245

246

1.2.2. From the bone marrow to iron: bone marrow is a prominent player in systemic iron metabolism

247

Bone marrow, erythrocyte production, and spleen erythrocyte degradation participate in the systemic distribution of iron. Once produced inside the bone marrow, erythrocytes are released into the plasma in order to help oxygenate the body. Circulating red blood cells contain half the total quantity of whole-body iron, *i.e.* approximately 1.5 to 2 g of iron. After 120 days, senescent erythrocytes are degraded within macrophages that release iron from hemoglobin. Iron then reenters the iron cycle without being excreted.

254 Bone marrow also plays a critical role in systemic iron regulation by modulating the expression of 255 hepcidin (Fig. 2). The main bone marrow factors that may ultimately regulate hepcidin are GDF15 256 (growth and differentiation factor 15) (48), TWSG1 (twisted gastrulation BMP signaling modulator 1) 257 (49), and the hormone erythroferrone (encoded by the gene ERFE) (6, 7, 12). During 258 dyserythropoiesis, as seen for instance in thalassemia major or intermedia (50-52) or in MDS (5, 53), 259 those factors secreted by the bone marrow may negatively impact hepcidin synthesis, leading to hepcidin deficiency and, in turn, to hypersideremia and subsequently body iron overload (54-56), 260 261 even prior to any transfusion. Bair et al. (57) showed that allogeneic T-replete stem cell 262 transplantation alters iron homeostasis in non-obese diabetic/severe combined immunodeficient 263 (NOD/SCID) mice, by downregulating liver hepcidin synthesis ahead of upregulating duodenal 264 ferroportin.

In summary, we have shown in this first section that iron is an essential player of bone marrow functions through its implication in proliferation/apoptosis and differentiation of all hematopoietic lineages. In return, the bone marrow impacts the systemic homeostasis of iron by the massive release of iron after erythrophagocytosis, the major source of circulating iron, and by modulating two crucial hormones of iron metabolism, hepcidin and erythroferrone. Having described the normal functional

270	relationships between iron and the bone marrow, we next explore pathological aspects o	f this
271	relationship. In the following sections, we report the causative links between iron and leukemi	a and
272	their clinical implications.	
273		

- 274
- 276

275 2. IRON STATUS IN LEUKEMIAS

277 2.1. The most suitable methods to assess body iron load in patients

278 Evaluating the total body iron load requires the use of reliable tools. In particular, it may not be 279 sufficient to rely exclusively on plasma ferritin levels in light of the numerous non-iron-related factors susceptible to induce hyperferritinemia (58, 59). In leukemia patients, these factors include 280 281 inflammation (60), the metabolic syndrome (61) and a high ferritin content within leukemic cells (25). 282 It should also be noted that plasma ferritin levels not only depend on the amount of cellular iron 283 deposition but also on the cellular iron distribution. For equivalent cellular iron concentrations, the 284 corresponding plasma ferritin levels are higher for macrophagic (typically transfusional) iron than for 285 parenchymal (hepatocyte) iron, as typically observed in iron excess related to ineffective 286 erythropoiesis (62). The clinician must keep this difference in mind since it may impact the threshold 287 ferritin values used for clinical decision-making when treating iron overload. Combining plasma 288 ferritin and transferrin saturation levels is especially informative, widely available, and cost-effective 289 for the clinician, although both measurements can be affected by inflammation and must be 290 interpreted with caution in this setting. In addition, ferritin can be affected by liver damage, and 291 transferrin saturation fluctuates diurnally and is also affected by cytolysis (63). However useful these 292 iron-related blood parameters may be, the main message is that it is of utmost importance to rely on 293 the direct visualization and quantification of the tissue iron content (especially in the liver and spleen) 294 in order to rigorously assess the body iron load. Non-invasive approaches such as magnetic resonance 295 imaging (MRI) should be preferentially used (64-67). MRI to determine the liver iron concentration 296 (LIC) has now largely replaced histological assessment by liver biopsy. However, MRI is not widely 297 available nor uniformly done. Bone marrow iron evaluation using MRI, the interest of which has 298 recently been reported for Gaucher disease (68), has not yet been fully evaluated in hematologic 299 malignancies (69). As an illustration of the superiority of MRI evaluation as compared to serum 300 ferritin for body iron load assessment, no hepatic iron overload was found in 13 out of 39 patients 301 who had a serum ferritin level over 1000 ng/mL (70) (71). The bone marrow iron score could be an 302 interesting indicator of secondary iron overload in acute myeloid leukemia patients (72). Dual-energy 303 computed tomography (73) may be a promising technique for the precise assessment of intrahepatic 304 iron distribution in transfusion-dependent patients with hematological malignancies (74).

305 In summary, the assessment of body iron stores is a two-step process. First, together with the 306 hemoglobin level, the reticulocyte count, red blood cell morphology, serum ferritin and transferrin 307 saturation must be checked. If both the ferritin and transferrin saturation parameters are normal, 308 reflecting an absence of iron excess, no further investigations are required. If they are elevated, and 309 after having checked for possible confounding factors, a direct evaluation of the tissue iron load is 310 required. MRI has currently become the preferred approach given its non-invasive nature, provided 311 it is available and affordable. Among the various methods, the signal intensity ratio method (64, 75) 312 is quite promising as it enables the direct assessment of the hepatic and splenic iron load without 313 requiring specific MRI equipment and provides free interpretation.

314

315 2.2. Iron status at diagnosis

316 It remains difficult to obtain precise data on the body iron status at the time of diagnosis since the 317 iron load check-up is usually done during or after chemotherapy and often from the perspective of 318 HSCT. However, Vag *et al.* (76) reported that LIC measured by MRI was close to normal in eight 319 patients with acute leukemia for whom the determination was performed within 10 days after therapy initiation. Moreover, the study by Moafi *et al.* (77), based on a histological evaluation of the bone marrow iron stores, reported that, when 30 acute lymphoblastic leukemia (ALL) patients at diagnosis were compared with 30 control subjects, the bone marrow iron score did not differ significantly whereas a significant elevation appeared in leukemia patients after one year of chemotherapy.

Altogether, those limited data suggest that the iron status at diagnosis of acute leukemia is not different from control subjects. However, larger cohorts and prospective studies are required to definitively conclude of this point.

328

329 2.3. Body iron load increases in leukemias, mainly due to iron input from blood transfusions

330

Body iron status has mostly been evaluated while leukemia was being treated. Altogether, the 331 number of studies remains limited when referring to the direct evaluation of body iron stores using 332 333 appropriate techniques (MRI or histology). Halonen et al. reported that 30 children with acute 334 lymphoblastic leukemia (ALL) of whom 19 (63%) had moderate iron overload as assessed by the total 335 iron score (78, 79). Vag et al. (76) showed that the mean LIC of 15 children (nine ALL, six AML (acute 336 myeloblastic leukemia)) was significantly increased compared to non-leukemic children. The mean 337 LIC was then correlated with the number of transfusions. Armand et al. (80) found that 85% of 48 338 patients with AML (n=29), ALL (n=11) or MDS (n=8) had a LIC value above the upper limit of normal 339 and, in 42% of patients, significant iron excess corresponded to more than three times the upper 340 limit of normal. Again, iron overload was correlated with the number of transfusions. In Trottier et 341 al.'s cohort (4) consisting of 37 leukemia case, eight out of 10 ALL patients and all of the AML patients 342 had an iron overload. A poor relationship was found between LIC and transfusion history. Maximova 343 N et al. performed an MRI-based evaluation of multiorgan iron load in pediatric patients who subsequently underwent hematopoietic stem cell transplantation (HSCT) (69). Among these patients, 344 345 21 had ALL and eight had AML. Thirteen ALL and all eight AML patients had a significantly elevated

LIC (>2-3 times the upper limit of normal) after HSCT. LIC was not found to be a reliable indicator of total body iron stores as indicated by marked discrepancies between LIC data and the iron estimation in the spleen or bone.

On the whole, for the previously mentioned studies, 49% (91/185) of the ALL or AML patients had significant iron overload before HSCT. In these hematologic malignancies (2, 3), transfusions appeared to be the main cause of the iron burden.

- 352
- 353 3. IS IRON A PREDISPOSING FACTOR TO LEUKEMIA?
- 354

355 3.1. The potential cellular toxicity of iron

Physiologically, most iron in the body is incorporated within molecular moieties that make it redoxinactive. For instance, iron is bound to plasma transferrin that ensures its transport, and iron is stored within cells in ferritin macromolecules that act as sponges preventing "unbound" or "free" cytosolic iron from being toxic. At the cellular level, a large quantity of iron is incorporated into heme as part of the hemoglobin molecule in erythroid cells, or myoglobin in muscle cells.

However, this protective process can be overridden in iron excess. This holds true when the plasma transferrin saturation with iron is over 45%, with the appearance of non-transferrin-bound iron (NTBI), and especially when the transferrin saturation becomes higher than 75% with the appearance of labile plasma iron (LPI). NTBI is thought to be under the biochemical form of low-molecular weight complexes (such as citrate and acetate), whereas LPI represents the potentially toxic form of circulating iron, defined by its propensity to generate reactive oxygen species (ROS), capable of

- 367 damaging the membranes of the cells, intracellular organelles and nuclei (17, 81, 82).
- 368 In summary, while iron is physiologically redox-inactive, iron excess, characterized by a plasma 369 transferrin saturation with iron over 45%, is toxic for the cells.
- 370
- 371

372

3.2. Experimental data converge to indicate the promoting role of iron on leukemia development

373

374 The promoting role of iron on tumor development has been explored in numerous types of cancer 375 (83) and the proliferative effect of iron is well documented (84, 85). Iron is also known to favor 376 genetic instability (82). Focusing on leukemia models, the following data were reported. Inoculated 377 L1210 cells (a mouse lymphocytic leukemia cell line) proliferated more in mice injected with iron than 378 in non-iron-treated control animals (86). Further experimental data shed some light on the possible 379 mechanistic impact of iron on tumorigenesis. Iron has been shown to reduce tumor suppressor p53 380 activity (87); however, two types of data do not fit with a promoting role of iron on tumorigenesis 381 through decreasing p53: on the one hand, iron favors ferroptosis, whereas the mechanism by which 382 p53 could sometimes favor tumorigenesis has been reported to be its suppressing effect on 383 metabolic stress-induced ferroptosis (88); on the other hand, p53 has been shown to decrease the NTBI transporter ZIP14 (also known as SLC39A14) (89), leading to decreased NTBI entry into tumor 384 385 cells and subsequently to decreased iron-related cell death. The precise role of iron on p53 regulation 386 and its effect needs further clarification. The Eltrombopag effect further illustrates the promoting 387 role of iron on leukemia cell growth. This compound is an oral small-molecule thrombopoietin 388 receptor (TPO-R also known as MLP) agonist used for treating chronic immune thrombocytopenic 389 purpura. However, independently of its TPO-R mediated effect, Eltrombopag is able to inhibit the 390 growth of human and murine leukemia cell lines by inducing differentiation and by slowing cell 391 division through blocking the cell cycle in the G1 phase. Interestingly, Eltrombopag decreased the 392 iron content within leukemic cells in a dose-dependent manner. Preloading cells with iron also 393 resulted in a rescue from the anti-proliferative and differentiation-inducing effects of Eltrombopag, 394 suggesting that the antileukemic effect of Eltrombopag is mediated through intracellular iron content 395 (90). Iron deprivation has been reported to induce monocyte differentiation of AML cells (91) and, 396 more generally, cellular iron-binding may be an interesting approach to counteract cancer through 397 the involvement of various signaling pathways (92). Finally, dihydorartemisinin has been reported to

induce acute myeloid leukemia cell death by inducing ferroptosis through the autophagy-dependent
degradation of ferritin (93).

In summary, experimental preclinical data converge to indicate the promoting role of iron on
leukemia development, and conversely, the role of iron chelation/deprivation to counteract cancer.

402

3.3. Is systemic iron overload in non-malignant hematological conditions a predisposition toleukemia?

405

406 3.3.1. Lessons from hemochromatosis, the archetype of systemic iron overload

407 Hemochromatosis is a genetic disorder characterized by diffuse body iron overload caused by 408 increased intestinal iron absorption, which itself is related to hepcidin deficiency (10). HFE is by far 409 the most frequently mutated gene found in hemochromatosis, with C282Y HFE mostly present in Caucasians. It is still being debated whether or not HFE-related genetic susceptibility to 410 411 hemochromatosis, and therefore iron excess, could favor the development of leukemia. A causative 412 link between the C282Y HFE mutation and ALL has not been clearly proven (94, 95) and the same 413 holds true for an association with the haplotype HLA-A3, known to be closely associated with the HFE gene (95). However, in a US cohort of 161 childhood ALL cases, Kennedy et al. (96) reported that the 414 risk of ALL was not only associated with C282Y and H63D HFE variants and S142G TFR1 (transferrin 415 416 receptor 1) variant, but also to some SNPs in other iron regulatory genes (SLC11A2 and TMPRSS6 417 genes). Although no data were given on the iron status of this cohort, these results strengthen the 418 view that iron overload mediated by genetic variants could contribute to a risk of ALL. No HFE 419 association has been reported with AML (97). It should be noted that only exceptional cases 420 associating HFE-related hemochromatosis and ALL have been reported (98).

421 Altogether, a genetic correlation has been found between some variant genes involved in iron 422 metabolism and ALL. The impact of the level of the iron burden is not clearly demonstrated as a cause 423 of those ALL. Moreover, in our opinion, despite the absence of an established link between

hemochromatosis (iron overload) and leukemia, it is important in clinical practice to check *HFE* mutations and, if negative, *non-HFE* mutations, in every leukemic patient with marked iron overload exhibiting the characteristic profile of hepcidin deficiency (increased plasma transferrin saturation associated with parenchymal, especially hepatocyte, iron overload (10, 52)) so as not to miss a coincidentally associated hemochromatosis (10).

429

430 3.3.2. Lessons from sickle cell disease and thalassemia, archetypes of secondary iron overload

431 Sickle cell disease and thalassemia are inherited disorders treated with chronic blood transfusions 432 resulting in diffuse body iron overload. Here again, very little data are available on the promoting 433 role of iron overload in leukemia transformation in these diseases. In sickle cell disease, an over two-434 fold increase in the risk of leukemia, mostly AML, has been reported in California (99) although it is 435 still unclear if iron overload was one of the risk factors in this study. In thalassemia, only exceptional 436 cases of leukemia have been described, suggesting a coincidental occurrence of these conditions 437 (100).

438

3.4. Is iron overload a factor favoring the transformation of myelodysplastic syndrome (MDS) intoleukemia?

441 MDS represents a particularly valuable experimental model and clinical situation for studying the role 442 of iron as a leukemia predisposing factor since MDS evolves towards AML transformation in 443 approximately one third of cases (101) (102). MDS encompasses a heterogeneous group of acquired 444 myeloid disorders leading to ineffective hematopoiesis with peripheral cytopenia(s) (103), among 445 which anemia is the most frequent. Patients with MDS can develop iron overload through repeated 446 blood transfusions and/or as a consequence of dyserythropoiesis.

447

448 3.4.1. Iron-related oxidative stress in MDS

450 It is now clear that MDS patients present increased oxidative stress that is further increased by iron 451 overload (104, 105), even in transfusion-independent cases (105). It has been proposed (106) that 452 iron deprivation by low-dose deferasirox can improve erythropoiesis in MDS. It should be noted, 453 however, that iron overload inhibited the proliferation of erythroid progenitor cells in MDS whereas 454 the myeloid compartment was not affected (107). All of the blood marrow cell types in 27 MDS 455 patients exhibited high ROS and low glutathion levels compared to 12 controls, with some correlation 456 with overall survival (108). Interestingly, Ghoti et al. found a correlation between ROS and serum 457 ferritin levels in the erythrocytes and platelets of low-grade MDS patients (109). Increased oxidative 458 DNA damage was found in MDS patients both on bone marrow cells (110) (however without 459 correlation with serum ferritin) and on peripheral blood mononuclear cells (111), with a protective 460 effect of oral iron chelation. Importantly, low-risk MDS patients have been reported to present the 461 highest ROS levels (108). Using NHD13 transgenic mice, a murine model of MDS, Chung et al. showed 462 that ROS may contribute to the progression of MDS to AML through ineffective DNA repair and 463 increased mutation frequency (112). Given the close relationship between iron and ROS, it is possible 464 that this progression was at least partly related to an iron effect (iron exposure, however, was not 465 used in this experiment).

466

3.4.2. The impact of dyserythropoiesis and erythroblastic mitochondrial iron overload in MDS to AML
 transformation

469

470 Iron overload due to dyserythropoiesis is mainly found in MDS with ring sideroblasts (MDS-RS), a
471 subgroup characterized by erythroblastic mitochondrial iron overload and a high frequency of
472 somatic mutations in the spliceosome gene *SF3B1* (113). Mean hepcidin levels are heterogeneous
473 across the different MDS subtypes, with the lowest levels in refractory anemia with ring sideroblasts
474 (now classified as MDS-RS with single dysplasia), which present the highest plasma NTBI levels (114475 116). Thus, MDS-RS patients have inappropriately low hepcidin levels, a typical feature of iron-

- 476 loading anemia (117). Most patients with MDS-RS with single dysplasia are stratified into the lower477 risk groups by the revised IPSS (118), pointing out that abnormal mitochondrial iron accumulation
 478 may not be a strong factor favoring leukemic transformation.
- 479

480 3.4.3. The impact of transfusional systemic iron overload in MDS to AML transformation

481

482 It has been reported that chronic red blood cell transfusions induce an iron overload that impacts 483 the survival of MDS patients (119). In a retrospective study of 467 MDS patients, the leukemia-free 484 survival of transfusion-dependent patients was significantly inferior to that of patients not requiring 485 transfusions, raising the possibility that transfusional iron overload may increase the risk of AML 486 transformation to leukemia (120). However, in a recent Brazilian study, hepatic iron overload, 487 measured by MRI and found in two-thirds of transfused and non-transfused MDS patients, was 488 associated with a lower overall survival, but was not correlated with an increased risk of AML 489 transformation (121). These results should nevertheless be considered in the light of the small cohort 490 size and the heterogeneous clinical status of the patients.

491 Although clinical data converge to indicate that blood transfusion dependency and an increasing 492 number of transfusions favor shorter overall survival and increase leukemic transformation in MDS 493 patients, it remains difficult to ascertain that these deleterious effects are related to iron overload 494 itself (5). Limiting and confounding factors may include: i) the fact that transfusion dependency could 495 reflect the overall disease severity; ii) the impact of comorbidities that are frequent in these elderly 496 patients; iii) the almost exclusive use of plasma iron parameters (especially ferritin levels) to estimate 497 body iron excess, which does not consistently reflect the iron store (as discussed in 2.1); and iv) the 498 risk of selection bias related to the possible proposal of chelation therapy to patients with a better 499 prognosis. Evaluating the impact of iron depletion by chelation therapy represents a "reverse" 500 approach to understanding the effect of iron excess on MDS to AML transformation. In this regard, 501 the repeatedly-found beneficial effect of iron chelation therapy (106, 122-126) represents an 502 important argument in favor of iron overload being responsible for promoting AML. In particular, the 503 TELESTO trial by Angelucci et al. (127), which is the sole prospective study randomizing deferasirox 504 vs. placebo in low-risk MDS patients, reports a favorable effect of iron chelation on event-free 505 survival, the rate of cardiac and hepatic events and the transformation to AML. However, it should 506 be kept in mind that part of the beneficial effect of the iron chelator deferasirox may be due not only 507 to iron chelation, but to well-documented associated hematopoietic effects (106, 125, 128-134). 508 Finally, regarding the specific effect of iron chelation on AML transformation, the Spanish Iron2 study 509 (126) identified a beneficial effect, although the German registry did not (123). 510 In summary, while systemic iron overload observed in hemochromatosis and sickle cell disease is not 511 512 clearly shown as a predisposing condition to leukemia, data are clearer for MDS. Some experimental studies suggest that iron may be a factor facilitating MDS to AML transformation, and bioclinical data 513 514 show that there is an increase in ROS production in MDS likely causing oxidative stress, including 515 oxidative DNA damage. Clinical data are still lacking, however, to firmly establish the causal relationship between iron overload and leukemia transformation in MDS. 516 517 518 519 4. THERAPEUTIC ASPECTS RELATED TO IRON OVERLOAD IN LEUKEMIA 520 521 4.1. Leukemia treatment and body iron burden 522 523 The impact of chemotherapy on iron metabolism: the transient appearance of NTBI 4.1.1.

524 Chemotherapy impacts iron metabolism through two mechanisms. The first one is that 525 chemotherapy causes iron excess when red blood cell transfusions are needed to counteract 526 chemotherapy-related anemia. A high amount of iron bound to hemoglobin is brought together 527 with massive erythrocyte supplementation. This iron, released from the erythrocytes during 528 erythrophagocytosis, will not be extracted out of the body since no specific iron excretion exists, 529 and will be stored within the organism. This corresponds to a net addition of iron. Another 530 mechanism is that chemotherapy favors the appearance of plasma NTBI. Harrison P et al. were the 531 first to report the presence of NTBI during chemotherapy, often concomitant with neutropenia 532 (135). In 23 out of 25 patients, labile plasma iron (LPI) levels increased 48 hours after the start of 533 conditioning pre-autologous HSCT, with a peak before cell infusion and a return to the normal range 534 at engraftment (136, 137). Studying a cohort of 30 patients with acute leukemia (16 AML and 14 535 ALL), Belotti et al. (138) showed that this peak of NTBI was found for all subsequent high-dose 536 chemotherapy courses. The appearance of NTBI during chemotherapy may be essentially due to 537 the massive iron release from the degradation of hemoglobinized bone marrow cells leading to 538 elevated transferrin saturation (139). The presence of NTBI can also be explained on the one hand by a decrease in NTBI uptake by the erythroid cells, given that such uptake has been demonstrated 539 540 in rat erythroid cells (140). Furthermore, it could be related to hypohepcidinemia due to the 541 absence of erythropoiesis. These different mechanisms can act simultaneously. Finally, high NTBI 542 levels were associated with a higher risk of sepsis (138). It should be noted that susceptibility to infection may be, by itself, an important factor in terms of the survival of patients with leukemia 543 undergoing chemotherapy. 544

545 As a whole, chemotherapy causes iron excess when red blood cell transfusions are provided and 546 favors the appearance of plasma NTBI.

547

548 4.1.2. The prognostic impact of body iron burden on hematopoietic stem cell transplantation549 (HSCT)

550 Numerous studies have concluded, overall, that high serum ferritin levels prior to HSCT are a 551 predictive factor of poor prognosis both in terms of morbidity and mortality. However, as previously

552 mentioned, hyperferritinemia clearly does not only reflect body iron overload, as this is notably an 553 inflammation marker (see reviews by Moukalled *et al.* (101), Isidori *et al.* (15); Leitch *et al.* (141), 554 Wang *et al.* (142), and Bertoli *et al.* (60)). This is why, in the present review, only studies using a 555 direct assessment, by MRI or histological studies, of the tissue iron concentration will be 556 considered.

557 A meta-analysis performed by Armand et al. (143) of four prospective studies (144) (4, 145, 146), 558 involving 144 AML, 90 ALL and approximately 50 MDS patients, concluded that iron overload was 559 not related to either overall survival or to non-relapse-mortality. However, one of the four studies 560 (145) was not in agreement with the other three, and meta-analysis bias due to a sample size issue 561 could not be totally excluded. Primarily, Wermke et al. (147) coordinated the first prospective, 562 German multicenter observational study (the ALLIVE study) assessing the relevance of 563 pretransplantation body iron overload measured by serum ferritin, transfusion burden, enhanced 564 LPI (defined as biologically active iron) and LIC (determined by MRI) in a cohort of hematopoietic 565 malignancies (92 AML and 20 MDS patients) undergoing HSCT. The results indicated that LIC values 566 more than three times the upper limit of normal were significantly associated with increased non-567 relapse mortality. It is still a possibility that this impact could be restricted to patients having 568 undergone a reduced-intensity conditioning regimen (this case concerns 83% of the studied 569 patients). Moreover, the ALLIVE study showed a significantly increased incidence of non-relapse 570 mortality in patients exhibiting a raised baseline enhanced-NTBI concentration. Moafi et al. (77) 571 concluded that high levels of bone marrow iron were associated with a poor response to treatment 572 and to the risk of relapse.

573 To summarize, body iron overload assessed by direct methods has a predictive value for poor 574 survival after HSCT. However, the predictive value of increased serum ferritin levels, which reflect 575 not only body iron excess but also other mechanisms, of which the foremost is inflammation, may 576 be stronger.

577

578

4.2. The impact of iron removal during leukemia treatment

579 4.2.1. Iron chelation

580 We will focus on the results obtained using oral iron chelation, especially deferasirox (DFX). Sivgin 581 et al. (148) retrospectively investigated 80 patients including 45 AML and 18 ALL patients for whom 582 the pretransplant serum ferritin levels were ≥ 1000 ng/mL. Thirty-seven patients were given DFX and compared to 26 patients who were phlebotomized due to DFX side effects or compliance 583 584 problems. Overall survival and disease-free survival were significantly better in the DFX group. The 585 first prospective multicenter clinical trial of DFX in adult allogeneic HSCT was carried out in Spain 586 (149). Thirty patients (including 17 AML patients and one ALL patient), with transfusional iron 587 overload (serum ferritin ≥ 1000 ng/mL or ≥ 20 units of packed red blood cells; the LIC assessment 588 was assessed by MRI, depending on equipment availability) received DFX at a starting dose of 10 589 mg/kg for 52 weeks or until the serum ferritin level was less than 400 ng/mL on two consecutive occasions. There were no severe drug-related adverse events. A significant reduction in ferritinemia 590 was observed from baseline to 52 weeks (1444 to 755 ng/mL) in the intent-to-treat population. LIC 591 592 was also significantly reduced for the seven patients for whom basal and final LIC (at 52 weeks) 593 could be obtained. The multicenter German study (DE02) (150) assessed the safety and efficacy of 594 DFX in 76 recipients of allogeneic HSCT (comprising 52 AML) who started at a dose of 10 mg/kg with 595 an escalating design up to 20 mg/kg. The median exposure was 330 days. Seventy-one percent of 596 the patients experienced drug-related adverse events (increased blood creatinine, nausea and 597 abdominal discomfort) leading to occasional discontinuation. The median compliance rate was > 598 80%. A significant decline in serum ferritin was observed (from 2045 to 957 ng/mL) and a negative 599 iron balance was obtained in 84% of patients.

In summary, these studies indicate that DFX is effective for iron chelation therapy after HSCT, with
a manageable safety profile. Gastrointestinal side effects may be reduced with the new DFX filmcoated tablet formulation (151, 152).

603

604 4.2.2. Phlebotomy

605 Iron removal by phlebotomy is the alternative to iron chelation for therapeutic iron removal. As to 606 the impact of phlebotomies in leukemia patients, most studies have involved patients after 607 allogeneic HSCT. We will focus here on those studies that used a direct evaluation of tissue iron 608 load by liver biopsy (153, 154) or imaging techniques (MRI (155) and, in one study, SQUID 609 (superconducting quantum interference device) (156)). All of the studies converged to conclude 610 that phlebotomy was a safe and well-tolerated procedure. A significant reduction in the liver iron 611 concentration (and serum ferritin) was obtained. A single retrospective study reported that DFX was more effective on iron excess than phlebotomy. However, only serum ferritin levels were 612 613 evaluated (148).

On the whole, further clinical studies should be carried out to ascertain if the long-term prognosis
after HSCT is favorably influenced by decreasing iron excess, through chelation or phlebotomy.
Irrespective of the therapeutic method, it should be emphasized that it is highly recommended to
avoid foods containing high amounts of iron since this is a natural and cheap way to counteract
intestinal iron absorption.

619

620 CONCLUSION

621 Close functional interactions exist physiologically between iron and bone marrow that concern the 622 leukocyte lineage as well as the erythroid cells. From a pathological point of view, iron acts as a co-623 carcinogenic factor that experimentally promotes leukemia cell growth, whereas clinical data 624 promoting the role of iron in MDS transformation is still under debate. Body iron overload, best assessed by direct MRI quantification, is usually not increased at the time of leukemia diagnosis; it
increases significantly during medical care, especially due to multiple transfusions. Iron overload,
notably through the damaging effects of NTBI, which is more likely to appear in the plasma with
chemotherapy, significantly contributes to a poor prognosis after HSCT. Hyperferritinemia only
partially reflects excess iron in the body but seems to be an interesting prognostic factor since it
also occurs in inflammation. Iron removal, mostly by oral chelation, must become the standard of
care whenever significant body iron overload has been firmly established.

632 FUTURE CONSIDERATIONS

In our opinion, increased awareness of the importance of diagnosing body iron excess in leukemia
 patients remains a key objective. Further clinical trials evaluating the long-term prognostic effect
 of iron removal by oral chelation are warranted, in principle, but may raise practical difficulties for
 recruiting patients. Strategies to target iron removal from specific tissues should be considered.

637

638 **PRACTICE POINTS**

- 639 Iron experimentally promotes leukemia cell growth; however, clinically, the promoting role of iron
 640 overload in the transformation of MDS into leukemia is still being debated.
- The assessment of body iron status in leukemia patients requires the direct visualization and
- 642 quantification of iron excess, especially by magnetic resonance imaging (MRI).
- Iron overload, mainly due to transfusions, is likely to contribute to a poor prognosis after
- 644 hematopoietic stem cell transplantation.
- 645 Hyperferritinemia is an interesting overall indicator of a poor prognosis; this parameter reflects
- 646 the inflammatory status and, albeit partially, the body iron burden.
- Iron removal by oral chelation or phlebotomies is well tolerated and acts efficient on the body
- 648 iron burden; its favorable effect on the long-term prognosis is uncertain.

649

650 **RESEARCH AGENDA**

• Further clinical trials investigating the impact of iron on MDS transformation, with appropriate
 measurement and follow-up of iron burden.

653

• Exploration of the promoting role of iron in the development of 654 myelodysplastic/myeloproliferative syndromes from hematopoietic stem cells especially by using 655 appropriate transgenic mouse models.

656

657

658

659 CONFLICT OF INTEREST

660 PB has been an occasional consultant and member of advisory board for Novartis. No links of interest

661 for the other authors in the frame of the present article.

663 **REFERENCES**

Muckenthaler MU, Rivella S, Hentze MW, Galy B. A Red Carpet for Iron Metabolism. Cell.
2017;168(3):344-61.

Paananen P, Arola MO, Pelliniemi TT, Salmi TT, Lahteenmaki PM. Evaluation of the effects of
different transfusion trigger levels during the treatment of childhood acute lymphoblastic leukemia. J
Pediatr Hematol Oncol. 2009;31(10):745-9.

669 3. Eng J, Fish JD. Insidious iron burden in pediatric patients with acute lymphoblastic leukemia.
670 Pediatr Blood Cancer. 2011;56(3):368-71.

4. Trottier BJ, Burns LJ, DeFor TE, Cooley S, Majhail NS. Association of iron overload with allogeneic
hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver
iron content. Blood. 2013;122(9):1678-84.

6745.Gattermann N. Iron overload in myelodysplastic syndromes (MDS). Int J Hematol. 2018;107(1):55-67563.

676 6. Kautz L, Nemeth E. Molecular liaisons between erythropoiesis and iron metabolism. Blood. 677 2014;124(4):479-82.

Miura S, Kobune M, Horiguchi H, Kikuchi S, Iyama S, Murase K, et al. EPO-R+ myelodysplastic cells
with ring sideroblasts produce high erythroferrone levels to reduce hepcidin expression in hepatic cells.
Blood Cells Mol Dis. 2019;78:1-8.

681 8. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425-33.

682 9. Brissot P, Loreal O. Iron metabolism and related genetic diseases: A cleared land, keeping 683 mysteries. J Hepatol. 2016;64(2):505-15.

684 10. Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Loreal O. Haemochromatosis. Nat
685 Rev Dis Primers. 2018;4:18016.

686 11. Coffey R, Ganz T. Iron homeostasis: An anthropocentric perspective. J Biol Chem. 687 2017;292(31):12727-34.

Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an
erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-84.

690 13. Ganz T. Erythropoietic regulators of iron metabolism. Free Radic Biol Med. 2019;133:69-74.

691 14. Pilo F, Angelucci E. A storm in the niche: Iron, oxidative stress and haemopoiesis. Blood Rev.
692 2018;32(1):29-35.

Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, et al. Iron toxicity - Its effect on the
bone marrow. Blood Rev. 2018.

595 16. Jin X, He X, Cao X, Xu P, Xing Y, Sui S, et al. Iron overload impairs normal hematopoietic stem and
596 progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice.
597 Haematologica. 2018;103(10):1627-34.

Lu W, Zhao M, Rajbhandary S, Xie F, Chai X, Mu J, et al. Free iron catalyzes oxidative damage to
hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload
patients. Eur J Haematol. 2013;91(3):249-61.

18. Chai X, Li D, Cao X, Zhang Y, Mu J, Lu W, et al. ROS-mediated iron overload injures the
hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice. Sci Rep.
2015;5:10181.

19. Borriello A, Caldarelli I, Speranza MC, Scianguetta S, Tramontano A, Bencivenga D, et al. Iron
overload enhances human mesenchymal stromal cell growth and hampers matrix calcification. Biochim
Biophys Acta. 2016;1860(6):1211-23.

70720.Okabe H, Suzuki T, Uehara E, Ueda M, Nagai T, Ozawa K. The bone marrow hematopoietic708microenvironment is impaired in iron-overloaded mice. Eur J Haematol. 2014;93(2):118-28.

709 21. Zheng Q, Zhao Y, Guo J, Zhao S, Fei C, Xiao C, et al. Iron overload promotes mitochondrial

fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation
 of the AMPK/MFF/Drp1 pathway. Cell Death Dis. 2018;9(5):515.

22. Laurell CB. Plasma iron and the transport of iron in the organism. Pharmacol Rev. 1952;4(4):371-95.

Summers M, Worwood M, Jacobs A. Ferritin in normal erythrocytes, lymphocytes, polymorphs,
and monocytes. Br J Haematol. 1974;28(1):19-26.

Summers MR, Jacobs A. Iron uptake and ferritin synthesis by peripheral blood leucocytes from
normal subjects and patients with iron deficiency and the anaemia of chronic disease. Br J Haematol.
1976;34(2):221-9.

Worwood M, Summers M, Miller F, Jacobs A, Whittaker JA. Ferritin in blood cells from normal
subjects and patients with leukaemia. Br J Haematol. 1974;28(1):27-35.

Guida C, Altamura S, Klein FA, Galy B, Boutros M, Ulmer AJ, et al. A novel inflammatory pathway
 mediating rapid hepcidin-independent hypoferremia. Blood. 2015;125(14):2265-75.

- Agoro R, Taleb M, Quesniaux VFJ, Mura C. Cell iron status influences macrophage polarization.
 PLoS One. 2018;13(5):e0196921.
- Wang L, Azad N, Kongkaneramit L, Chen F, Lu Y, Jiang BH, et al. The Fas death signaling pathway
 connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J Immunol.
 2008;180(5):3072-80.

Gordeuk VR, Ballou S, Lozanski G, Brittenham GM. Decreased concentrations of tumor necrosis
factor-alpha in supernatants of monocytes from homozygotes for hereditary hemochromatosis. Blood.
1992;79(7):1855-60.

- 30. Youssef LA, Rebbaa A, Pampou S, Weisberg SP, Stockwell BR, Hod EA, et al. Increased
 erythrophagocytosis induces ferroptosis in red pulp macrophages in a mouse model of transfusion. Blood.
 2018;131(23):2581-93.
- Haschka D, Petzer V, Kocher F, Tschurtschenthaler C, Schaefer B, Seifert M, Sopper S, Sonnweber
 T, Feistritzer C, Arvedson TL, Zoller H, Stauder R, Theurl I, Weiss G, Tymoszuk P. Classical and intermediate
 monocytes scavenge non-transferrin-bound iron and damaged erythrocytes. JCl Insight. 2019;8;4(8).
- Kramer JL, Baltathakis I, Alcantara OS, Boldt DH. Differentiation of functional dendritic cells and
 macrophages from human peripheral blood monocyte precursors is dependent on expression of p21
 (WAF1/CIP1) and requires iron. Br J Haematol. 2002;117(3):727-34.
- 33. Olakanmi O, Kesavalu B, Abdalla MY, Britigan BE. Iron acquisition by Mycobacterium tuberculosis
 residing within myeloid dendritic cells. Microb Pathog. 2013;65:21-8.

34. Stojanovic N, Jovcic G, Basara N, Pavlovic-Kentera V. Granulopoiesis in anemic Belgrade laboratory
(b/b) rats. Exp Hematol. 1990;18(5):379-83.

- 744 35. Borregaard N. Neutrophils, from marrow to microbes. Immunity. 2010;33(5):657-70.
- 745 36. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat
 746 Rev Immunol. 2013;13(3):159-75.

74737.Rosa L, Cutone A, Lepanto MS, Paesano R, Valenti P. Lactoferrin: A Natural Glycoprotein Involved748in Iron and Inflammatory Homeostasis. Int J Mol Sci. 2017;18(9).

- 38. Delforge A, Stryckmans P, Prieels JP, Bieva C, Ronge-Collard E, Schlusselberg J, et al. Lactoferrin:
 its role as a regulator of human granulopoiesis? Ann N Y Acad Sci. 1985;459:85-96.
- 39. Curran CS, Bertics PJ. Lactoferrin regulates an axis involving CD11b and CD49d integrins and the
 chemokines MIP-1alpha and MCP-1 in GM-CSF-treated human primary eosinophils. J Interferon Cytokine
 Res. 2012;32(10):450-61.
- 754 40. Neckers LM, Cossman J. Transferrin receptor induction in mitogen-stimulated human T
 755 lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2. Proc Natl
 756 Acad Sci U S A. 1983;80(11):3494-8.
- 757 41. Ned RM, Swat W, Andrews NC. Transferrin receptor 1 is differentially required in lymphocyte
 758 development. Blood. 2003;102(10):3711-8.
- 759 42. Barton JC, Wiener HW, Acton RT, Go RC. Total blood lymphocyte counts in hemochromatosis
- probands with HFE C282Y homozygosity: relationship to severity of iron overload and HLA-A and -B allelesand haplotypes. BMC Blood Disord. 2005;5:5.

762 43. Cruz E, Melo G, Lacerda R, Almeida S, Porto G. The CD8+ T-lymphocyte profile as a modifier of iron
763 overload in HFE hemochromatosis: an update of clinical and immunological data from 70 C282Y
764 homozygous subjects. Blood Cells Mol Dis. 2006;37(1):33-9.

Arezes J, Costa M, Vieira I, Dias V, Kong XL, Fernandes R, et al. Non-transferrin-bound iron (NTBI)
uptake by T lymphocytes: evidence for the selective acquisition of oligomeric ferric citrate species. PLoS
One. 2013;8(11):e79870.

Pinto JP, Arezes J, Dias V, Oliveira S, Vieira I, Costa M, et al. Physiological implications of NTBI
uptake by T lymphocytes. Front Pharmacol. 2014;5:24.

46. Porto G, De Sousa M. Iron overload and immunity. World J Gastroenterol. 2007;13(35):4707-15.

47. Dorner MH, Silverstone A, Nishiya K, de Sostoa A, Munn G, de Sousa M. Ferritin synthesis by
human T lymphocytes. Science. 1980;209(4460):1019-21.

Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia
suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096-101.

Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, et al. Identification of TWSG1
as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood.
2009;114(1):181-6.

Tanno T, Miller JL. Iron Loading and Overloading due to Ineffective Erythropoiesis. Adv Hematol.
2010;2010:358283.

780 51. Camaschella C, Nai A. Ineffective erythropoiesis and regulation of iron status in iron loading
781 anaemias. Br J Haematol. 2016;172(4):512-23.

52. Brissot P, Troadec MB, Loreal O, Brissot E. Pathophysiology and classification of iron overload
diseases; update 2018. Transfus Clin Biol. 2018.

78453.Angelucci E, Cianciulli P, Finelli C, Mecucci C, Voso MT, Tura S. Unraveling the mechanisms behind785iron overload and ineffective hematopoiesis in myelodysplastic syndromes. Leuk Res. 2017;62:108-15.

Figeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific
gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during
iron overload. J Biol Chem. 2001;276(11):7811-9.

Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. Lack of hepcidin gene
expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc
Natl Acad Sci U S A. 2001;98(15):8780-5.

792 56. Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93(4):1721-41.

79357.Bair S, Spaulding E, Parkkinen J, Shulman HM, Lesnikov V, Beauchamp M, et al. Transplantation of794allogeneic T cells alters iron homeostasis in NOD/SCID mice. Blood. 2009;113(8):1841-4.

795 58. Brissot P. Comment je traite une hyperferritinémie. Hématologie. 2015;21:139-45.

59. Brissot E, Savani BN, Mohty M. Management of high ferritin in long-term survivors after
 hematopoietic stem cell transplantation. Semin Hematol. 2012;49(1):35-42.

60. Bertoli S, Paubelle E, Berard E, Saland E, Thomas X, Tavitian S, et al. Ferritin heavy/light chain
(FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute
myeloid leukemia. Eur J Haematol. 2019;102(2):131-42.

801 61. DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, et al. Metabolic
802 Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive
803 Practice Recommendations from the CIBMTR and EBMT. Biol Blood Marrow Transplant. 2016;22(8):1493804 503.

805 62. Musallam KM, Taher AT. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 806 2011;364(15):1476.

80763.Brissot P. BE. Comment j'interprète la saturation de la transferrine. Hématologie. 2017;23:406-80812.

64. Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, et al. Non-invasive assessment of
hepatic iron stores by MRI. Lancet. 2004;363(9406):357-62.

811 65. Wood JC. Estimating tissue iron burden: current status and future prospects. Br J Haematol. 812 2015;170(1):15-28. 813 66. St Pierre TG, El-Beshlawy A, Elalfy M, Al Jefri A, Al Zir K, Daar S, et al. Multicenter validation of
814 spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration.
815 Magn Reson Med. 2014;71(6):2215-23.

816 67. Rose C, Vandevenne P, Bourgeois E, Cambier N, Ernst O. Liver iron content assessment by routine
817 and simple magnetic resonance imaging procedure in highly transfused patients. Eur J Haematol.
818 2006;77(2):145-9.

819 68. Regenboog M, Bohte AE, Akkerman EM, Stoker J, Hollak CEM. Iron storage in liver, bone marrow
820 and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment. Br J
821 Haematol. 2017;179(4):635-47.

- 69. Maximova N, Gregori M, Boz G, Simeone R, Zanon D, Schillani G, et al. MRI-based evaluation of
 multiorgan iron overload is a predictor of adverse outcomes in pediatric patients undergoing allogeneic
 hematopoietic stem cell transplantation. Oncotarget. 2017;8(45):79650-61.
- 70. Olcay L, Hazirolan T, Yildirmak Y, Erdemli E, Terzi YK, Arda K, et al. Biochemical, radiologic,
 ultrastructural, and genetic evaluation of iron overload in acute leukemia and iron-chelation therapy. J
 Pediatr Hematol Oncol. 2014;36(4):281-92.

Majhail NS, Lazarus HM, Burns LJ. A prospective study of iron overload management in allogeneic
hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2010;16(6):832-7.

830 72. Hoeks M, van der Pol M, Middelburg R, Evers D, van Kraaij M, Zwaginga JJ. Bone marrow iron
831 score as an indicator for secondary iron overload in acute myeloid leukemia patients. Eur J Haematol.
832 2018.

833 73. Goo HW, Goo JM. Dual-Energy CT: New Horizon in Medical Imaging. Korean J Radiol.
834 2017;18(4):555-69.

Kobayashi H, Yoshimura N, Uemura S, Katagiri T, Tanaka T, Ushiki T, et al. Heterogeneity of
intrahepatic iron deposition in transfusion-dependent iron overload patients with hematological
malignancies. Leuk Res. 2018;70:41-4.

838 75. d'Assignies G, Paisant A, Bardou-Jacquet E, Boulic A, Bannier E, Laine F, et al. Non-invasive
839 measurement of liver iron concentration using 3-Tesla magnetic resonance imaging: validation against
840 biopsy. Eur Radiol. 2018;28(5):2022-30.

76. Vag T, Kentouche K, Krumbein I, Reichenbach JR, Lopatta E, Renz DM, et al. Noninvasive
measurement of liver iron concentration at MRI in children with acute leukemia: initial results. Pediatr
Radiol. 2011;41(8):980-4.

- 77. Moafi A, Ziaie M, Abedi M, Rahgozar S, Reisi N, Nematollahi P, et al. The relationship between iron
 bone marrow stores and response to treatment in pediatric acute lymphoblastic leukemia. Medicine
 (Baltimore). 2017;96(44):e8511.
- 78. Halonen P, Mattila J, Suominen P, Ruuska T, Salo MK, Makipernaa A. Iron overload in children who
 are treated for acute lymphoblastic leukemia estimated by liver siderosis and serum iron parameters.
 Pediatrics. 2003;111(1):91-6.

850 79. Deugnier Y, Turlin B. Pathology of hepatic iron overload. Semin Liver Dis. 2011;31(3):260-71.

851 80. Armand P, Kim HT, Rhodes J, Sainvil MM, Cutler C, Ho VT, et al. Iron overload in patients with 852 acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow 853 Transplant. 2011;17(6):852-60.

854 81. Brissot P, Ropert M, Le Lan C, Loreal O. Non-transferrin bound iron: A key role in iron overload 855 and iron toxicity. Biochim Biophys Acta. 2012;1820:403-10.

856 82. Troadec MB, Loreal O, Brissot P. The interaction of iron and the genome: For better and for worse.
857 Mutat Res. 2017;774:25-32.

858 83. Beguin Y, Aapro M, Ludwig H, Mizzen L, Osterborg A. Epidemiological and nonclinical studies 859 investigating effects of iron in carcinogenesis--a critical review. Crit Rev Oncol Hematol. 2014;89(1):1-15.

860 84. Chenoufi N, Drenou B, Loreal O, Pigeon C, Brissot P, Lescoat G. Antiproliferative effect of 861 deferiprone on the Hep G2 cell line. Biochem Pharmacol. 1998;56(4):431-7.

862 85. Gaboriau F, Leray AM, Ropert M, Gouffier L, Cannie I, Troadec MB, et al. Effects of deferasirox and 863 deferiprone on cellular iron load in the human hepatoma cell line HepaRG. Biometals. 2010;23(2):231-45. 864 86. Bergeron RJ, Streiff RR, Elliott GT. Influence of iron on in vivo proliferation and lethality of L1210 865 cells. J Nutr. 1985;115(3):369-74.

866 87. Shen J, Sheng X, Chang Z, Wu Q, Wang S, Xuan Z, et al. Iron metabolism regulates p53 signaling
867 through direct heme-p53 interaction and modulation of p53 localization, stability, and function. Cell Rep.
868 2014;7(1):180-93.

869 88. Tarangelo A, Magtanong L, Bieging-Rolett KT, Li Y, Ye J, Attardi LD, et al. p53 Suppresses Metabolic
870 Stress-Induced Ferroptosis in Cancer Cells. Cell Rep. 2018;22(3):569-75.

871 89. Zhao N, Zhang AS, Wortham AM, Jue S, Knutson MD, Enns CA. The Tumor Suppressor, P53,
872 Decreases the Metal Transporter, ZIP14. Nutrients. 2017;9(12).

- 873 90. Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, et al. Eltrombopag inhibits the
 874 proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood.
 875 2012;120(2):386-94.
- 876 91. Callens C, Coulon S, Naudin J, Radford-Weiss I, Boissel N, Raffoux E, et al. Targeting iron
 877 homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid
 878 leukemia. J Exp Med. 2010;207(4):731-50.

879 92. Lui GY, Kovacevic Z, Richardson V, Merlot AM, Kalinowski DS, Richardson DR. Targeting cancer by
880 binding iron: Dissecting cellular signaling pathways. Oncotarget. 2015;6(22):18748-79.

93. Du J, Wang T, Li Y, Zhou Y, Wang X, Yu X, et al. DHA inhibits proliferation and induces ferroptosis
of leukemia cells through autophagy dependent degradation of ferritin. Free Radic Biol Med.
2019;131:356-69.

884 94. Dorak MT, Mackay RK, Relton CL, Worwood M, Parker L, Hall AG. Hereditary hemochromatosis
885 gene (HFE) variants are associated with birth weight and childhood leukemia risk. Pediatr Blood Cancer.
886 2009;53(7):1242-8.

887 95. Rodriguez-Lopez R, Donoso M, Fernandez-Cavada M, Gonzalez LM, Margallo A, Corral C, et al.
888 Diagnostic utility of HFE variants in Spanish patients: association with HLA alleles and role in susceptibility
889 to acute lymphoblastic leukemia. Gene. 2013;514(1):31-5.

890 96. Kennedy AE, Kamdar KY, Lupo PJ, Okcu MF, Scheurer ME, Baum MK, et al. Examination of HFE
891 associations with childhood leukemia risk and extension to other iron regulatory genes. Leuk Res.
892 2014;38(9):1055-60.

893 97. Dorak MT, Burnett AK, Worwood M. HFE gene mutations in susceptibility to childhood leukemia:
894 HuGE review. Genet Med. 2005;7(3):159-68.

895 98. Balagtas JM, Dahl GV. Therapeutic complications in a patient with high-risk acute lymphoblastic
896 leukemia and undiagnosed hereditary hemochromatosis. Pediatr Blood Cancer. 2012;58(1):101-3.

897 99. Brunson A, Keegan THM, Bang H, Mahajan A, Paulukonis S, Wun T. Increased risk of leukemia
898 among sickle cell disease patients in California. Blood. 2017;130(13):1597-9.

899 100. Alavi S, Safari A, Sadeghi E, Amiri S. Hematological malignancies complicating beta-thalassemia
900 syndromes: a single center experience. Blood Res. 2013;48(2):149-51.

Moukalled NM, El Rassi FA, Temraz SN, Taher AT. Iron overload in patients with myelodysplastic
 syndromes: An updated overview. Cancer. 2018 ; 124 (20) ; 3979-3989.

903 102. Hasserjian RP. Myelodysplastic Syndrome Updated. Pathobiology. 2018:1-7.

904 103. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the
905 World Health Organization classification of myeloid neoplasms and acute leukemia. Blood.
906 2016;127(20):2391-405.

907 104. de Souza GF, Barbosa MC, Santos TE, Carvalho TM, de Freitas RM, Martins MR, et al. Increased 908 parameters of oxidative stress and its relation to transfusion iron overload in patients with 909 myelodysplastic syndromes. J Clin Pathol. 2013;66(11):996-8.

Saigo K, Takenokuchi M, Hiramatsu Y, Tada H, Hishita T, Takata M, et al. Oxidative stress levels in
myelodysplastic syndrome patients: their relationship to serum ferritin and haemoglobin values. J Int Med
Res. 2011;39(5):1941-5.

913 106. Meunier M, Ancelet S, Lefebvre C, Arnaud J, Garrel C, Pezet M, et al. Reactive oxygen species levels

control NF-kappaB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic
 syndromes. Oncotarget. 2017;8(62):105510-24.

916 107. Hartmann J, Braulke F, Sinzig U, Wulf G, Maas JH, Konietschke F, et al. Iron overload impairs
917 proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. Leuk
918 Res. 2013;37(3):327-32.

919 108. Goncalves AC, Cortesao E, Oliveiros B, Alves V, Espadana AI, Rito L, et al. Oxidative stress and
920 mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and
921 prognosis: A pilot study. Free Radic Res. 2015;49(9):1081-94.

922 109. Ghoti H, Amer J, Winder A, Rachmilewitz E, Fibach E. Oxidative stress in red blood cells, platelets
923 and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol.
924 2007;79(6):463-7.

110. Novotna B, Bagryantseva Y, Siskova M, Neuwirtova R. Oxidative DNA damage in bone marrow
cells of patients with low-risk myelodysplastic syndrome. Leuk Res. 2009;33(2):340-3.

111. Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, et al. Improvement of iron-mediated
oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment
with deferasirox. Free Radic Biol Med. 2012;53(4):643-8.

112. Chung YJ, Robert C, Gough SM, Rassool FV, Aplan PD. Oxidative stress leads to increased mutation
frequency in a murine model of myelodysplastic syndrome. Leuk Res. 2014;38(1):95-102.

Malcovati L, Cazzola M. Recent advances in the understanding of myelodysplastic syndromes with
 ring sideroblasts. Br J Haematol. 2016;174(6):847-58.

114. Cortelezzi A, Cattaneo C, Cristiani S, Duca L, Sarina B, Deliliers GL, et al. Non-transferrin-bound
iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J. 2000;1(3):153-8.

936 115. Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N, et al. Hepcidin levels and their
937 determinants in different types of myelodysplastic syndromes. PLoS One. 2011;6(8):e23109.

Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, et al. Dyserythropoiesis evaluated
by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk
myelodysplastic syndromes. Haematologica. 2019;104(3):497-504.

941 117. Ambaglio I, Malcovati L, Papaemmanuil E, Laarakkers CM, Della Porta MG, Galli A, et al.
942 Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic
943 mutation of SF3B1. Haematologica. 2013;98(3):420-3.

Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with
thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". Am J Hematol. 2019.

946 119. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and
947 life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical
948 decision making. J Clin Oncol. 2005;23(30):7594-603.

120. Leitch HA, Buckstein R, Zhu N, Nevill TJ, Yee KWL, Leber B, et al. Iron overload in myelodysplastic
syndromes: Evidence based guidelines from the Canadian consortium on MDS. Leuk Res. 2018;74:21-41.

121. Mantovani LF, Santos FPS, Perini GF, Nascimento CMB, Silva LP, Wroclawski CK, et al. Hepatic and
cardiac and iron overload detected by T2* magnetic resonance (MRI) in patients with myelodisplastic
syndrome: A cross-sectional study. Leuk Res. 2019;76:53-7.

122. Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron
overload using iron chelation therapy. Leuk Res. 2007;31 Suppl 3:S7-9.

Neukirchen J, Fox F, Kundgen A, Nachtkamp K, Strupp C, Haas R, et al. Improved survival in MDS
patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Dusseldorf
MDS registry. Leuk Res. 2012;36(8):1067-70.

Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, et al. Adequate iron chelation
therapy for at least six months improves survival in transfusion-dependent patients with lower risk
myelodysplastic syndromes. Leuk Res. 2014;38(5):557-63.

962 125. Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, et al. Deferasirox for
963 transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA
964 MDS0306 Trial). Eur J Haematol. 2014;92(6):527-36.


Remacha AF, Arrizabalaga B, Villegas A, Duran MS, Hermosin L, de Paz R, et al. Evolution of iron
overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ
complications. Ann Hematol. 2015;94(5):779-87.

- Angelucci E LJ, Greenberg PL, et al. Safety and efficacy, including event-free survival, of deferasirox
 versus placebo in iron-overloaded patients with low- and int-1-risk myelodysplastic syndromes (MDS):
- 970 outcomes from the randomized, double-blind Telesto study. Abstract #234. Presented at the 2018 ASH
 971 Annual Meeting, December 1, 2018; San Diego, CA.
- 972 128. Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A, et al. Hematologic
 973 responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
 974 Haematologica. 2012;97(9):1364-71.
- 129. List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, et al. Deferasirox reduces
 serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic
 syndrome. J Clin Oncol. 2012;30(17):2134-9.
- 130. Molteni A, Riva M, Pellizzari A, Borin L, Freyrie A, Greco R, et al. Hematological improvement
 during iron-chelation therapy in myelodysplastic syndromes: the experience of the "Rete Ematologica
 Lombarda". Leuk Res. 2013;37(10):1233-40.
- 131. Improta S, Villa MR, Volpe A, Lombardi A, Stiuso P, Cantore N, et al. Transfusion-dependent lowrisk myelodysplastic patients receiving deferasirox: Long-term follow-up. Oncol Lett. 2013;6(6):1774-8.
- 132. Cheong JW, Kim HJ, Lee KH, Yoon SS, Lee JH, Park HS, et al. Deferasirox improves hematologic and
 hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional
 iron overload patients with myelodysplastic syndrome or aplastic anemia. Transfusion. 2014;54(6):154251.
- 987 133. Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and
 988 potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124(6):873-81.
- 989 134. Shapira S, Raanani P, Samara A, Nagler A, Lubin I, Arber N, et al. Deferasirox selectively induces
 990 cell death in the clinically relevant population of leukemic CD34(+)CD38(-) cells through iron chelation,
 991 induction of ROS, and inhibition of HIF1alpha expression. Exp Hematol. 2019;70:55-69 e4.
- Harrison P, Marwah SS, Hughes RT, Bareford D. Non-transferrin bound iron and neutropenia after
 cytotoxic chemotherapy. J Clin Pathol. 1994;47(4):350-2.
- 136. Naoum FA, Esposito BP, Ruiz LP, Ruiz MA, Tanaka PY, Sobreira JT, et al. Assessment of labile plasma
 iron in patients who undergo hematopoietic stem cell transplantation. Acta Haematol. 2014;131(4):2226.
- 137. Naoum FA, Esposito BP, Cancado RD. Impact of conditioning and engraftment on iron status in
 hematopoietic stem cell transplantation: Contribution of labile plasma iron. Hematol Oncol Stem Cell
 Ther. 2016;9(4):165-7.
- 1000 138. Belotti A, Duca L, Borin L, Realini S, Renso R, Parma M, et al. Non transferrin bound iron (NTBI) in 1001 acute leukemias throughout conventional intensive chemotherapy: kinetics of its appearance and 1002 potential predictive role in infectious complications. Leuk Res. 2015;39(1):88-91.
- 1003 139. Porter JB, Walter PB, Neumayr LD, Evans P, Bansal S, Garbowski M, et al. Mechanisms of plasma
 1004 non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia
 1005 with sickle cell and thalassaemia patients. Br J Haematol. 2014;167(5):692-6.
- 1006140.Morgan EH. Mechanisms of iron transport into rat erythroid cells. J Cell Physiol. 2001;186(2):193-1007200.
- 1008 141. anLeitch HA, Fibach E, Rachmilewitz E. Toxicity of iron overload and iron overload reduction in the
 1009 setting of hematopoietic stem cell transplantation for hematologic malignancies. Crit Rev Oncol Hematol.
 1010 2017;113:156-70.
- 1011 142. Wang Z, Jia M, Zhao H, Cheng Y, Luo Z, Chen Y, et al. Prognostic impact of pretransplantation
 1012 hyperferritinemia in adults undergoing allogeneic hematopoietic SCT: a meta-analysis. Bone Marrow
 1013 Transplant. 2014;49(10):1339-40.
- 1014 143. Armand P, Kim HT, Virtanen JM, Parkkola RK, Itala-Remes MA, Majhail NS, et al. Iron overload in 1015 allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant. 1016 2014;20(8):1248-51.
- 1017 144. Armand P, Sainvil MM, Kim HT, Rhodes J, Cutler C, Ho VT, et al. Does iron overload really matter 1018 in stem cell transplantation? Am J Hematol. 2012;87(6):569-72.

- 1019 145. Wermke M, Schmidt A, Middeke JM, Sockel K, von Bonin M, Schonefeldt C, et al. MRI-based liver
 iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell
 transplantation. Clin Cancer Res. 2012;18(23):6460-8.
- 146. Virtanen JM, Itala-Remes MA, Remes KJ, Vahlberg T, Saunavaara JP, Sinisalo M, et al. Prognostic
 impact of pretransplant iron overload measured with magnetic resonance imaging on severe infections in
 allogeneic stem cell transplantation. Eur J Haematol. 2013;91(1):85-93.
- 1025 147. Wermke M, Eckoldt J, Gotze KS, Klein SA, Bug G, de Wreede LC, et al. Enhanced labile plasma iron
 1026 and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic
 1027 cell transplantation (ALLIVE): a prospective, multicentre, observational trial. Lancet Haematol.
 1028 2018;5(5):e201-e10.
- 1029 148. Sivgin S, Baldane S, Akyol G, Keklik M, Kaynar L, Kurnaz F, et al. The oral iron chelator deferasirox
 1030 might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional
 1031 iron overload. Transfus Apher Sci. 2013;49(2):295-301.
- 1032 149. Vallejo C, Batlle M, Vazquez L, Solano C, Sampol A, Duarte R, et al. Phase IV open-label study of
 1033 the efficacy and safety of deferasirox after allogeneic stem cell transplantation. Haematologica.
 1034 2014;99(10):1632-7.
- 1035 150. Jaekel N, Lieder K, Albrecht S, Leismann O, Hubert K, Bug G, et al. Efficacy and safety of deferasirox
 1036 in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell
 1037 transplantation. Bone Marrow Transplant. 2016;51(1):89-95.
- 1038 151. Kattamis A, Aydinok Y, Taher A. Optimising management of deferasirox therapy for patients with
 1039 transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes. Eur J Haematol.
 1040 2018;101(3):272-82.
- 1041 152. Taher AT, Origa R, Perrotta S, Kouraklis A, Belhoul K, Huang V, et al. Influence of patient-reported
 1042 outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the
 1043 ECLIPSE trial: A post hoc mediation analysis. Am J Hematol. 2019;94(4):E96-E9.
- 1044 153. Tomas JF, Pinilla I, Garcia-Buey ML, Garcia A, Figuera A, Gomez-Garcia de Soria VGG, et al. Long1045 term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61
 1046 patients. Bone Marrow Transplant. 2000;26(6):649-55.
- 1047 154. Kamble RT, Selby GB, Mims M, Kharfan-Dabaja MA, Ozer H, George JN. Iron overload manifesting
 1048 as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell
 1049 transplantation. Biol Blood Marrow Transplant. 2006;12(5):506-10.
- 1050 155. Kew AK, Clarke S, Ridler A, Burrell S, Edwards JA, Doucette S, et al. A prospective cohort study of
 1051 the feasibility and efficacy of iron reduction by phlebotomy in recipients of hematopoietic SCT. Bone
 1052 Marrow Transplant. 2015;50(3):457-8.
- 1053 156. Busca A, Falda M, Manzini P, D'Antico S, Valfre A, Locatelli F, et al. Iron overload in patients 1054 receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a 1055 superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Biol 1056 Blood Marrow Transplant. 2010;16(1):115-22.
- 1057

1058 FIGURE LEGENDS

1059





1067

1068

FIGURE 2. Bone marrow and iron metabolism. Due to iron toxicity, malignancy or chemotherapy, the functionality of bone marrow stem cells (BMSC) can be altered, leading, for the erythroid cell lineage, to dyserythropoiesis, which in turn causes an increased production of various factors including GDF15 and the hormone erythroferrone. These factors lead to a decrease in hepcidin production, then to an increase of plasma iron and, through non-transferrin bound iron, to iron deposition into various parenchymal cells (in first line the hepatocytes): it may lead to body iron overload (this iron excess can increase hepcidin but the increasing signal remains dominated by the reverse impact of dyserythropoiesis (and anemia itself)).

1076





Gene name and aliases	Gene symbol (Official, others)
aconitase 1, soluble	ACO1 <u>; IRP1</u> ; IREB1; IREBP
ceruloplasmin	СР
erythroferrone	ERFE, FAM132B
ferritin, heavy polypeptide 1	FTH1 ; FTH
ferritin, light polypeptide	FTL ; L-ferritin
ferroportin ; solute carrier family 40 (iron- regulated transporter), member 1	SLC40A1 ; IREG1 ; MTP1; SLC11A3; FPN
hemochromatosis	<u>HFE</u> ; HH; HFE1; HLA-H
hepcidin ; human anti-microbial peptide	HAMP ; HEPC ; LEAP1
hephaestin	HEPH ; CPL
iron-responsive element binding protein 2	IREB2 <u>; IRP2</u> ; ACO3; IRP2AD
thrombopoietin Receptor	MPL, <u>TPO-</u> R
transferrin	TF
transferrin receptor	TFRC ; <u>TFR1</u> ; TFR; CD71
transferrin receptor 2	TFR2

Table 1 : Principal iron regulatory genes presented in the review, with their multiple gene symbols. We have underlined the names and/or symbols used in the review.